Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

GAR Helps Counter Legal Pitfalls of Cancer Screening, Diagnosis

June 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--Put GAR in your patients' records. It can prove extremely useful should you find yourself being sued for medical malpractice, Marvin A. Dewar, MD, JD, said at the National Conference on Prevention and Early Detection, sponsored by the American Cancer Society.

WASHINGTON--Put GAR in your patients' records. It can prove extremelyuseful should you find yourself being sued for medical malpractice,Marvin A. Dewar, MD, JD, said at the National Conference on Preventionand Early Detection, sponsored by the American Cancer Society.

GAR is an acronym for "general information, alternatives,risks"--three key points every physicians needs to discusswith patients before cancer screening or diagnosis,

Dr. Dewar, director, Family Practice Residency Program, the Universityof Florida College of Medicine, Gainesville, said that malpracticecases alleging that a physician delayed diagnosis or failed todiagnose a cancer continue to increase.

In a 1991 Florida study, Dr. Dewar and his colleagues found thatin cases involving primary care physicians, failure to diagnosecancer was the most common allegation, representing 16% of allpaid claims, at an average cost of $160,352. Failure to diagnosebreast cancer ranked first, followed by lung, prostate, and coloncancer.

One element in defending against such lawsuits is having and documentinga good informed consent process. And thus, he recommends rememberingGAR.

"Informed consent is a conversation that you as providershave with patients," Dr. Dewar said. "It is the understanding,the meeting of the minds between the patient and the provider.The documentation of the informed consent is not informed consent,but it is important from the legal protection standpoint."

He urged that physicians give each patient general information,explain the alternatives, describe the risks, and note this inthe patient's record.

"A plastic surgeon or a breast surgeon will dictate voluminousand detailed informed consent," Dr. Dewar said. "Atthe cancer detection level, you and I often don't have time todo that. Nonetheless, documentation is important, and I suggestthat you do it."

Impact of Practice Guidelines

Clinical practice guidelines have been the subject of much debateabout whether they increase the risk of malpractice litigationor protect providers and decrease the threat. In fact, such guidelinescan prove to be a mixed blessing. The most helpful practice guidelinesfor physicians, Dr. Dewar commented, are those that are widelyaccepted by the medical community.

In areas where guidelines diverge or conflict, practice recommendations"are not going to carry very much legal weight," hesaid, "because they will be just as confusing to the juryas they are to many providers and patients."

More relevant to malpractice suits are guidelines developed specificallyto address situations that commonly lead to litigation. But mostimportant, practice guidelines "have to be straightforwardand readily interpreted in the litigation setting," Dr. Dewarsaid.

For example, he said, the American Cancer Society's guidelinesfor screening intervals are very simple, clear, and easily understood."They will have more weight in a litigation setting thanwill more lengthy and confusing guidelines."

Defining Medical Negligence

Legally, to succeed in winning compensation in a malpractice suit,a patient must prove medical negligence, and this essentiallyconsists of four points.

First, an obligation must exist that the provider give a certainlevel of care; second, that duty must be breached; third, thatbreach must cause harm to the patient; and fourth, that harm mustinflict legally recognizable damage, such as loss of wages, onthe patient.

Originally, local medical standards served as the criteria fordetermining a physician's standard of care; now physicians facea national standard. "Although the resources may be different,the standard of care that you provide with those resources isgoing to be the same in Wisconsin as it is in Atlanta," Dr.Dewar commented.

However, physicians do have what attorneys call the "respectableminority rule" on their side. This is especially importantin such areas as prostate screening that are marked by scientificcontroversy and varying recommendations and practice guidelines.

"If the care decision that you go by is supported by whatwe call a respectable minority of the medical profession, then,in fact, you have not breached the duty of care," Dr. Dewarsaid. "So in an area where there is tremendous scientificdebate, the clinician is not going to be put on the hook, theoretically,for following one of the viable options."

However, where one practices can make a difference in the criteriafor proving harm, legally referred to as "causation."Most states use "the 51% rule," Dr. Dewar said, whichmeans that "the breach of duty had to be the probable causeof the injury, with a 51% chance that the failure to do something,or the doing of something that shouldn't have been done, led tothe injury."

A minority of states, including Illinois and West Virginia, usea more stringent rule, such as the physician's action resultingin "some loss of chance of a better outcome," and theserules work more to the plaintiff's advantage," he said.

The large majority of medical malpractice suits never stay thefull legal course from accusation to jury verdict, he said. Nationally,73% of medical malpractice cases end in settlement, with another10% dismissed by the courts.

One of physicians' greatest malpractice fears--the awarding ofpunitive damages--is actually quite rare in the health-care setting,Dr. Dewar said, since they require proof of willful and wantonnegligent conduct.

Articles in this issue

Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down
Pain Scale Resembling Thermometer May Be Easier to Use Than VAS
Immediate Hormone Therapy Improves Prostate Cancer Survival
New Test for Prostate Cancer Risk
Topotecan: Significant Activity in Ovarian Cancer
Prostate Cancer Guideline Classifies Patients By Risk Status
New Monograph Describes Racial/Ethnic Cancer Patterns in the US
Moral Challenges Ahead as Managed Care Marches On
One Doctor Tells His Experience With Hospital Mergers
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

Tim Cortese
August 2nd 2025
Article

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 2nd 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 2nd 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 2nd 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 2nd 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.


The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Tim Cortese
August 2nd 2025
Article

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Related Content

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

Tim Cortese
August 2nd 2025
Article

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 2nd 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 2nd 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 2nd 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 2nd 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.


The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Tim Cortese
August 2nd 2025
Article

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.